MEL-PLEX partner Prof Francesco Cecconi and his team at the Danish Cancer Society Research Center was awarded DKK 3,820,000.00 (~ €515,000.00) over the next 3 years to support the project entitled “The pro-autophagic tumor suppressor AMBRA1 as a novel therapeutic target for melanoma”.
Deadline for application: December 5th 2017
We are currently recruiting an early stage researcher for MEL-PLEX Project 12. The position will be available from January 2nd, 2018 for 6 months.
The successful candidate will be hosted at OncoMark (Ireland).
OncoMark is currently involved in a number of EU funded projects, including the pan-European academic/private sector research training network project called MEL-PLEX –Identifying and validating a panel of master transcriptional regulators in advanced melanoma, using a systems transcriptomics and histology approach (Project 12).
Specific melanoma cohort data has been analysed and key network targets that regulate transcription have been identified. The candidate will validate these potential targets using tissue analysis techniques (WB, IHC) and process the data using advanced digital image analysis, statistical analysis and data driven systems modeling.
On June 28th MEL-PLEX Project Coordinator Prof Markus Rehm received the “Ireland’s Champions of EU Research” recognition awarded by Enterprise Ireland on a special ceremony hosted at the Royal Hospital Kilmainham in Dublin.
The consortium partner OncoMark received a Special Award for its high success in EU funded projects.
More information can be found here.
Regulators in the United States and Europe have approved Amgen’s talimogene laherparepvec, a genetically modified live oncolytic herpesvirus therapy that replicates inside cancer cells and causes them to rupture and die. More information here.